

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**ZJ**

**中基長壽科學**

ZHONG JI LONGEVITY SCIENCE

**Zhong Ji Longevity Science Group Limited**

**中基長壽科學集團有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 767)**

## **RESIGNATION OF EXECUTIVE DIRECTORS AND CHANGE OF CHIEF EXECUTIVE OFFICER**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Zhong Ji Longevity Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Yan Yifan (“**Mr. Yan**”) has resigned as an executive Director and chief executive officer and Ms. Cao Xie Qiong (the “**Ms. Cao**”) has resigned as an executive Director of the Company, all with effect from 17 October 2025, as Mr. Yan and Ms. Cao wish to devote more time to their personal and other business commitments.

Mr. Yan and Ms. Cao have confirmed to the Board that they have no disagreement with the Board and there is no matter relating to their resignations that need to be brought to the attention of the shareholders of the Company. The Board would like to take this opportunity to express its appreciation to Mr. Yan and Ms. Cao for their contribution to the Company during their tenure of office.

### **APPOINTMENT OF CHIEF EXECUTIVE OFFICER**

The Board is also pleased to announce that Mr. Yan Li (“**Mr. Yan Li**”), an executive Director, has been appointed as the Chief Executive Officer of the Company, with effect from 17 October 2025.

The biographical details of Mr. Yan Li are set out as follows:

Mr. Yan Li, aged 54, joined the Company as an executive Director in November 2020, was appointed as the Chairman of the Board and the chairman of the nomination committee of the Board in December 2020 and was appointed the chairman of share award committee of the Board in May 2021. He received the award of International Honorary Fellow of Greenville University in the United States in 2020, was the vice president of Shenzhen Non-Governmental Organization Federation and the vice president of Shenzhen General Chamber of Commerce. Mr. Yan Li has over 10 years' experience in management and administration in the fields of advanced medical and biological technology. In 2014, he founded Zhong Ji 1 International Medical Group (HK) Limited ("**HK Zhong Ji 1**") and is currently a director and the chief executive officer of HK Zhong Ji 1. HK Zhong Ji 1 is dedicated to integrate leading resources about the health of knee joint around the globe and establish the world's leading international advanced medical transformation platform through cell testing, cell storage and enhancement, cell and gene therapies and the research and development, transformation and sale of biotechnology products. The Asian Integrated Cell Laboratory under HK Zhong Ji 1 is the world's leading autoimmune cell bank. Currently, Mr. Yan Li also holds directorships in the Company's subsidiaries.

As at the date of this announcement, Mr. Yan Li is beneficially interested in 94,655,145 Shares, representing approximately 14.87% of the total number of Shares in issue. Save as disclosed above, Mr. Yan Li has confirmed that he (i) does not have any relationship with any Director, senior management, or substantial or controlling shareholder (as defined in the Listing Rules) of the Company; (ii) does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the SFO; (iii) does not hold any other directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not hold any other positions in the Group.

Mr. Yan Li has entered into an appointment letter with the Company pursuant to which he agreed to act as an executive Director subject to retirement by rotation and re-election (if applicable) at an annual general meeting at least once every three years in accordance with the Bye-laws and the Corporate Governance Code set out in Appendix 14 to the Listing Rules with effect from 13 November 2020. Pursuant to the appointment letter entered into by the Company and Mr. Yan Li and the Company regarding his appointment as the Chief Executive Officer of the Company, Mr. Yan Li shall receive an annual remuneration of HK\$1,200,000, which was determined by the Board based on the recommendation of the remuneration committee of the Company with reference to his qualification, duties and responsibilities within the Group, as well as the prevailing market conditions.

Following the appointment of Mr. Yan Li as the Chief Executive Officer of the Company, Mr. Yan Li now serves as both the chairman of the Board and the Chief Executive Officer of the Company, such practice deviates from code provision C.2.1 of

the Corporate Governance Code (the “**CG Code**”) as set forth in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The Board believes that vesting the roles of both chairman and chief executive in the same individual can ensure consistent leadership within the Group and enables more effective and efficient overall strategic planning for the Group. The Board further believes that the balance of power and authority for the present arrangement will not be impaired and is adequately ensured by the current Board which comprises experienced and high caliber individuals with sufficient number thereof being independent non-executive Directors. Therefore, the Board considers that the deviation from the code provision C.2.1 of the CG Code is appropriate in such circumstances. In addition, under the supervision of the Board, which is comprised of two executive Directors, two non-executive Directors and three independent non-executive Directors, the Board is appropriately structured with a balance of power to provide sufficient checks to protect the interests of the Company and the shareholders of the Company.

Save as disclosed above, the Board is not aware of any other matters relating to the appointment of Mr. Yan Li as Chief Executive Officer that need to be brought to the attention of the shareholders of the Company and there is no other information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

By order of the Board  
**Zhong Ji Longevity Science Group Limited**  
**Yan Li**  
*Chairman and Executive Director*

Hong Kong, 17 October 2025

As at the date of this announcement, the Directors are:

*Executive Directors*

Mr. Yan Li (*Chairman*)  
Mr. Li Xiaoshuang

*Independent Non-executive Directors*

Mr. Lee See Barry  
Mr. Huang Jiang  
Prof. Huang Cibo

*Non-executive Directors*

Dr. He Yiwu  
Mr. Lyu Changshang

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*